<h1>Jubilant Ingrevia Grants 42,298 Stock Options Under Employee Scheme</h1>
The Nomination, Remuneration and Compensation Committee of Jubilant Ingrevia Limited approved the grant of stock options to eligible employees under the Jubilant Ingrevia Employees Stock Option Scheme 2021. This approval followed a meeting held on Wednesday, July 22, 2026.
The committee authorized the granting of a total of 42,298 stock options to employees. These options were designated as either Restricted Stock Units (RSUs) or Performance Linked Stock Units (PSUs).
Details regarding the granted options and associated terms are summarized below:
| Item | Detail |
|---|---|
| Total Options Granted | 42,298 |
| Type of Grant | Restricted Stock Units (RSUs) and Performance Linked Stock Units (PSUs) |
| Stock Details | Equity Shares with a face value of Re.1/- each |
| Exercise Price | Re. 1/- per equity share, corresponding to the face value |
Scheme Terms and Conditions
The stock options are subject to specific vesting schedules and performance requirements as outlined in the scheme documentation.RSUs will vest at the end of three years from the grant date, while PSUs are set to vest at the end of one year from the grant date. For RSUs, eligibility is based on employee tenure and rating, whereas PSU grants depend on fulfilling specified performance parameters.
Options granted under this scheme must be exercised within one year from their vesting date, subject to the terms defined in the Jubilant Ingrevia Employees Stock Option Scheme 2021.
JUBLINGREA Stock Price Movement
Jubilant Ingrevia Limited sheds value in live trading, slipping 1.49% as of 11:13 AM with shares currently priced at ₹752.45. The stock traded a volume of 117,304 shares during the day, having shed ₹11.35 from its previous close.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.